Category Archives: New York Stem Cells

NEW YORK, Oct. 13, 2014 /PRNewswire/ -- The key to Transforming Future of Diagnostic and Therapeutic Medicine

This study investigates the global stem cell market for the period 2013 to 2018. The geographic regions covered in the study are the North America, Europe and APAC, followed by a detailed Asia Pacific Region Analysis, which covers countries such as India, Australia, Thailand, Singapore, South Korea, Malaysia and Japan. The stem cell market is covered into four broad segments, namely by products, by technology and by application. The study covers various areas of interest such as regulatory policies within stem cell research, key business updates, analysis of risk factors, and strategic recommendations. Additionally, key clinical milestones, timelines of key clinical events, key companies to watch, and a strategic partnership assessment in the global stem cell market have been included.

Key Findings -The global market for stem cell was $ billion in 2013 and is expected to reach $ billion in 2018, growing at a robust CAGR of% from 2013 to 2018. -The worldwide market for adult stem cell is estimated to be at $billion in 2013 and is projected to reach $ billion by 2018. Adult stem cells constitute % of the total stem cell market. -Cord blood banking is one of the fastest growing segments of the stem cell market. The number of active cord blood banks worldwide have grown from mere in 2005 to over in 2013. -North America's total stem cell market was valued at $ billion in 2013 and is projected to increase to $ billion by 2018. -The European stem cell market was valued at $billion in 2013 and is projected to increase to $billion by 2018. -The Asia-Pacific (APAC) stem cell market was valued at $ billion in 2013 and is projected to increase to $billion by 2018. -APAC countries are progressing fast in the field of various stem cells research, including human embryonic stem cells, induced pluripotent stem cell (IPSc) and others. The major hurdle has been the regulatory environment in these countries, but that has been changing lately. Several Asian countries have modified their regulations regarding stem cell research to attract more investors. -India, Singapore and South Korea are the frontrunners and are expected to dominate the APAC stem cells market in the coming years. Favourable regulatory changes and funding support from governments have helped the commercialization of the stem cells industry. -Indian stem cell market was estimated to be $ million in 2013 and is expected to grow at a CAGR of % from 2013 to 2018. -Current penetration of stem cell banking in Singapore is % and is expected to grow at a CAGR of % in next years. -South Korea is all set to lead the stem cell research in APAC. Funding in stem cell in this country could be compared to that of US. -Stem cells obtained from adult organisms constitute the main focus of research and the ethics surrounding the use of these cells are quite undisputed. Therapies employing adult stem cells are being developed by various companies (such as ViaCell, StemSource, Osiris Therapeutics, Neural Stem, and Angioblast) and are moving fast from laboratory to the clinical application phase. -Majority of companies pursuing stem cell therapeutics are engaged in the development of adult stem cells derived from sources such as bone marrow, neural tissue, adipose tissue, menstrual blood, and placenta.

Read the full report: http://www.reportlinker.com/p02414037-summary/view-report.html

About Reportlinker ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

RELATED LINKS http://www.reportlinker.com

See original here:
Analysis of the Global Stem Cell Market

BOSTON Harvard researchers have pioneered a technique to grow by the billions the insulin-producing cells diabetics lack, a breakthrough that could lead to new ways to treat the disease.

The breakthrough occurs after 15 years of seeking a bulk recipe for making beta cells, which sense the level of sugar in the blood and keep it in a healthy range by making precise amounts of insulin, according to Harvard scientists led by Douglas Melton, who published their work recently in the journal Cell.

The process begins with human stem cells, which have the ability to become any type of tissue or organ.

The technique is an important step toward understanding and treating diabetes, a condition in which the pancreas's beta cells are insufficient or dead. Diabetes affects 347 million people worldwide, and the high blood sugar levels it causes can damage patients' hearts, eyes, kidneys, nervous systems and other tissues.

This is part of the holy grail of regenerative medicine or tissue engineering: trying to make an unlimited source of cells or tissues or organs that you can use in a patient to correct a disease, said Albert Hwa, director of discovery science at JDRF, a New York-based diabetes advocacy group that funded Melton's work.

The procedure for making mature, insulin-secreting beta cells has taken years of painstaking research that led to a 30-day, six-step recipe, Melton said. Laboratories will be able to use the cells to test drugs and learn more about how diabetes occurs, he said.

Susan Solomon, chief executive of the New York Stem Cell Foundation, said the discovery is so significant that it could shift the direction of diabetes research.

It's a new game, she said.

They had to go through an awful lot of trial and error to get to this, said Jeanne Loring, director of The Scripps Research Institute's Center for Regenerative Medicine in La Jolla, Calif. The proof will be in how well this protocol works for people in other laboratories.

People with type 2 diabetes, in which the body loses its ability to produce insulin over time, usually take drugs that boost its production. About 15 percent of patients with type 2 can't make enough of the hormone, even with drug treatment, and must take daily injections to replace it, Melton said.

Continue reading here:
Harvard makes diabetes breakthrough

New York, New York (PRWEB) September 24, 2014

Americord announced today that it has provided funding to support a clinical trial investigating the efficacy of autologous umbilical cord blood for the treatment of pediatric patients with cerebral palsy.

This trial is being conducted under the direction of an internationally renowned expert in umbilical cord blood transplantation. The purpose is to determine whether infusions of a child's own cord blood can lessen the symptoms of cerebral palsy. The goal of the trial explores the potential of discovering how cord blood could be used for other purposes, including reducing inflammation in the brain and producing new hormones to repair damaged brain cells.

This research for children with cerebral palsy is truly exciting, said Americord CEO Martin Smithmyer. We will be following this trial with great interest and we are thrilled to provide funding to help support it. Americords funding has been made through its corporate giving program, which was established to support research focused on the therapeutic uses of stem cells from umbilical cord blood, cord tissue, and placenta tissue.

About Americord Registry

Americord Registry is a leader in the advancement of umbilical cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company's laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. Visit http://americordblood.com/ for more information.

###

More here:
Americord Backs Another Cord Blood Clinical Trial

New York, NY (PRWEB) September 22, 2014

Video: Preventing Diabetes After Pancreatectomy - Dr. Beth Schrope

NewYork-Presbyterian/Columbia University Medical Center now offers autologous islet cell transplantation, or auto islet surgery, to prevent diabetes in patients who require a total pancreatectomy. The hospital is the first center in the New York metropolitan area to offer this treatment.

Every year, roughly 87,000 people in the United States receive surgical treatment for pancreatitis, a debilitating condition that causes intense abdominal pain and, potentially, diabetes. Pancreatitis can be so painful that, in some cases, patients must have the entire pancreas removed. While surgery relieves pain in 90 percent of cases, patients are left without the ability to produce insulin, causing a difficult-to-treat form of Type 1 diabetes known as brittle diabetes.

In auto islet surgery, the patient's islet cells, which produce hormones that regulate the endocrine system, are extracted from the pancreas after it is removed. The cells are then processed and reinfused into the patients liver. When auto islet surgery is successful, the reinfused cells produce insulin, acting in place of the pancreas to regulate blood sugar.

The most recent findings show that about one third of patients require no insulin therapy after autologous islet transplantation, another third require some insulin therapy after the procedure, and the procedure is unsuccessful in preventing diabetes in the remaining third.

"The goal of pancreatectomy is to relieve pain," says Dr. Beth Schrope, gastrointestinal surgeon and assistant professor of surgery, NewYork-Presbyterian/Columbia University Medical Center, who specializes in the treatment of pancreatitis. Returning to normal activities and living without pain is a tremendous improvement in patients' quality of life. Now with islet transplantation, theres an added bonusthe possible prevention of diabetes."

NewYork-Presbyterian/Columbia University Medical Center is currently accepting patients for auto islet surgery, through a joint effort of NewYork-Presbyterian/Columbia's Pancreas Center and the Stem Cell Processing and Cell Therapy Laboratory of the Department of Pathology. Patients who need a total pancreatectomy for benign diseases (such as chronic pancreatitis) may be eligible for this procedure to avoid Type 1 diabetes.

NewYork-Presbyterian Hospital/Columbia University Medical Center

NewYork-Presbyterian Hospital/Columbia University Medical Center, located in New York City, is one of the leading academic medical centers in the world, comprising the teaching hospital NewYork-Presbyterian and its academic partner, Columbia University College of Physicians and Surgeons. NewYork-Presbyterian/Columbia provides state-of-the-art inpatient, ambulatory and preventive care in all areas of medicine, and is committed to excellence in patient care, research, education and community service. NewYork-Presbyterian Hospital also comprises NewYork-Presbyterian Hospital/Weill Cornell Medical Center, NewYork-Presbyterian/Morgan Stanley Childrens Hospital, NewYork-Presbyterian Hospital/Westchester Division, NewYork-Presbyterian/The Allen Hospital and NewYork-Presbyterian/Lower Manhattan Hospital. The hospital is also closely affiliated with NewYork-Presbyterian/Lawrence Hospital in Bronxville. NewYork-Presbyterian is the #1 hospital in the New York metropolitan area, according to U.S. News & World Report, and consistently named to the magazines Honor Roll of best hospitals in the nation. For more information, visit http://www.nyp.org.

Go here to read the rest:
New Treatment May Prevent Diabetes After Pancreatitis Surgery

SEPTEMBER 15, 2014

TiGenix to participate or present at key conferences in the second half of 2014

Leuven (BELGIUM) - September 15, 2014 - TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today the list of conferences in which it will participate during the second half of 2014.

15-16 September Stem Cells & Regenerative Medicine Congress 2014, Boston, USA Participant: Claudia Jimenez, Senior Director Business Development

17 September Regener8, Leeds, UK Presenter: Wilfried Dalemans, Chief Technical Officer

30 September-1 October 14th Biotech in Europe Forum for Global Partnering and Investing, Basel, Switzerland Participant: Claudia Jimenez, Senior Director Business Development

2-3 October 14th Large & Midcap Event, Paris, France Participant: Claudia D'Augusta, Chief Financial Officer

6-8 October Stem Cell Meeting on the Mesa, California, USA Presenter: Eduardo Bravo, Chief Executive Officer

18-22 October 22nd United European Gastroenterology Week (UEGW), Vienna, Austria Participant: Mary Carmen Diez, VP Medical Affairs and New Product Commercialisation

3-5 November BIO-Europe 2014, Frankfurt, Germany Participant: Claudia Jimenez, Senior Director Business Development

Read more here:
TiGenix: TiGenix to participate or present at key conferences in the second half of 2014

Boston, MA (PRWEB) September 11, 2014

A promising first-in-class drug that stimulates the creation of new nerve cells in the brains of "Alzheimer's mice," will soon be tested in the brains of human patients with the promise it can help people in the early stages of the disease.

New research by Dr. Sam Gandy of Mount Sinai School of Medicine in New York and recently published in the journal Molecular Psychiatry outlines the extraordinary promise of the drug, known as an "mGluR2/3 blocker."

The learning behavior of Alzheimer's mice being treated with the mGluR2/3 blocker has been sustained at normal levels, Gandys study has revealed, in contrast to the steady decline of mice not being treated.

"It's extraordinary that, in such a short time, we have moved from ordinary skin cells to induced pluripotent stem cells in a Petri dish, to lab-generated human nerve cells, and now to a drug that could potentially create those cells inside a human brain," said Gandy.

"We realize that we are unlikely to have much impact in late stage Alzheimer's, but we are cautiously hopeful that this drug might arrest Alzheimer's disease at an early stage so that patients can remain functional for more extended periods."

The drug originally caught the attention of Gandy and his team for its possible ability to inhibit production of the toxic amyloid beta 42, associated with Alzheimer's disease. Created by the Japanese pharmaceutical firm Taisho and originally studied for depression, the drug acts by stimulating stem cells in the hippocampus to divide and form new nerve cells.

With funding from Cure Alzheimer's Fund, Gandys team conducted a pilot study of the drug's effects on a particular strain of mice. That study produced such promising results that it has drawn $1 million in funding from the Veterans Administration "MERIT Review" program that supports Gandy's lab at the James J. Peters VA Medical Center in the Bronx. The Louis B. Mayer Foundation and the Sarah and Gideon Gartner Foundation provided additional funding.

The mGluR2/3 blocker has also been administered to healthy young human subjects, and so far has seen to be safe. The next step for Gandy's team will be to treat elderly human subjects with the drug to test safety in this population before gearing up to test the drug in Alzheimer's patients.

The mGluR2/3 blocker is one of the few drugs being researched that holds promise for repairing brains damaged by neurodegenerative disease.

Link:
New Drug Study Offers Promise of Brain Cell Regeneration for Alzheimers Patients

Updated: 09/05/2014 6:04 PM Created: 09/05/2014 5:38 PM WNYT.com By: Benita Zahn

Blood transfusions go hand in hand with high dose chemotherapy to save the lives of cancer patients. But too often, doctors worry there will be blood when it's needed.

Dr.Sami Brake is a cancer specialist at New York Oncology- Hematology. He says "We run short of platelets, of blood products all the time. So it's important for people in the community to be aware of this problem that we have all the time."

Many of the treatments he relies on depress a patient's ability to make new blood cells, so donated blood is critical to their survival. When there's a lag between ordering treatment and blood arriving, sometimes from hours away, it's worrisome. And it's not something cancer patients like Cindy Applebaum need to have on their mind.

" When they basically tell you they're killing everything inside of your body. Your entire immune system is completely wiped out" says Cindy.

That's what she endured in advance of her stem cell transplant with her own stem cells to fight her blood cancer: multiple myeloma. In short, without donated blood she could never have survived the treatment that's her only chance for remission of her disease.

" You're at rock bottom, I guess, is the best way to describe it. And the blood and platelets actually help enhance the growth of the new cells that you need to survive" she says.

Cindy's two, grown kids were at her side through her treatment - along with her brothers, other family and dear friends. All critical to her well being. But she's clear -- while their support and love is invaluable, it was the kindness of strangers who gave the gift of life, that gave her the chance for survival.

"It really takes everybody in the community fighting for it."

You can donate blood on Monday, September 8 at our Save a Life Blood Drive.

Go here to see the original:
Donate blood and join in on the fight against cancer

Aug. 6, 2014

Colleagues of Yoshiki Sasai, leading Japanese life science researcher, say he has taken his own life; Sasai was co-author of discredited stem cell study published in journal Nature that was retracted due to factual errors and allegations of misconduct. MORE

Journal Nature retracts two scientific papers it published that initially electrified biologists by describing easy way to make stem cells; says papers were error-filled and had not been verified by anyone else. MORE

Op-Ed article by evolutionary geneticist Svante Paabo warns against using sequenced genomes of Neanderthals to re-create Neanderthal individuals; contends from an ethical perspective such an idea should be condemned, and argues that using stem cells to create cells and tissues in test tubes for research is far more ethically defensible and technically feasible. MORE

Scientists, reporting in journal Cell Stem Cell, move step closer to goal of creating stem cells perfectly matched to a patients DNA in order to treat diseases; say they have created patient-specific cell lines for 'therapeutic cloning' out of skin cells of two adult men. MORE

Japanese research institute concludes that study published in journal Nature that was once hailed as breakthrough in creating stem cells contains fabricated and doctored images that cast doubt on its findings; singles out study's lead author Haruko Obokata, stem cell biologist, saying she had altered or misrepresented illustrations in her research papers. MORE

Japanese research institute acknowledges that study billed as breakthrough in stem cell research contained spliced image, material recycled from lead author's doctoral thesis, and other mistakes; disclosure threatens to discredit newly acclaimed researcher Haruko Obokata, whose team found that simple acid bath might turn cells in the body into stem cells; findings appeared in journal Nature. MORE

Teruhiko Wakayama, one of the authors of startling study that claimed to have found a simple way to make stem cells, says he is no longer sure of its conclusions; calls for its retraction. MORE

Study published in journal Nature finds that simple acid bath might turn out to be quicker and easier source of multipurpose stem cells than methods now in use; technique was developed by researchers at Riken Center for Developmental Biology in Kobe, Japan, and Brigham and Womens Hospital and Harvard Medical School in Boston MORE

Stem cell clinics in United States and Mexico, like Regenerative Medicine Institute in Tijuana, are offering unproven stem cell treatments for high price to desperate clients, posing challenge for scientists who are moving cautiously and seeking more data; efficacy and safety of such treatments remains in question. MORE

Read more from the original source:
Stem Cells - The New York Times

SYDNEY, Sept. 3, 2014 /PRNewswire/ -- Novogen Ltd. (ASX: NRT, NASDAQ: NVGN) today announced that Graham Kelly PhD, CEO, will present at the Rodman & Renshaw 16th Annual Healthcare Conference on Wednesday, September 10th in New York. Dr. Kelly will provide an overview of the two Novogen first-in-class drug technology platforms in the field of oncology. His presentation will take place at the New York Palace Hotel and will begin at 10:25am.

About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT-based joint venture company, CanTx Inc, with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on the Company's website,www.novogen.com.

For more information please contact:

Corporate Contact

Media enquiries

Executive Chairman & CEONovogen GroupGraham.Kelly@novogen.com+61 (0) 2 9472 4100

In the USA:

Read the original post:
Novogen Announces Presentation at Rodman & Renshaw 16th Annual Healthcare Conference

PUBLIC RELEASE DATE:

28-Aug-2014

Contact: James Devitt james.devitt@nyu.edu 212-998-6808 New York University

New York University biologists have identified a mechanism that helps explain how the diversity of neurons that make up the visual system is generated.

"Our research uncovers a process that dictates both timing and cell survival in order to engender the heterogeneity of neurons used for vision," explains NYU Biology Professor Claude Desplan, the study's senior author.

The study's other co-authors were: Claire Bertet, Xin Li, Ted Erclik, Matthieu Cavey, and Brent Wellsall postdoctoral fellows at NYU.

Their work, which appears in the latest issue of the journal Cell, centers on neurogenesisthe process by which neurons are created.

A central challenge in developmental neurobiology is to understand how progenitorsstem cells that differentiate to form one or more kinds of cellsproduce the vast diversity of neurons, glia, and non-neuronal cells found in the adult Central Nervous System (CNS). Temporal patterning is one of the core mechanisms generating this diversity in both invertebrates and vertebrates. This process relies on the sequential expression of transcription factors into progenitors, each specifying the production of a distinct neural cell type.

In the Cell paper, the researchers studied the formation of the visual system of the fruit fly Drosophila. Their findings revealed that this process, which relies on temporal patterning of neural progenitors, is more complex than previously thought.

They demonstrate that in addition to specifying the production of distinct neural cell type over time, temporal factors also determine the survival or death of these cells as well as the mode of division of progenitors. Thus, temporal patterning of neural progenitors generates cell diversity in the adult visual system by specifying the identity, the survival, and the number of each unique neural cell type.

The rest is here:
NYU researchers ID process producing neuronal diversity in fruit flies' visual system